Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial
IntroductionThe role of prednisone in the prevention of androgen receptor antagonist-related rash and treatment for metastatic hormone-sensitive prostate cancer (mHSPC) is unclear. This pilot trial (ChiCTR2200060388) aimed to investigate the feasibility of apalutamide combined with androgen deprivat...
Tallennettuna:
| Päätekijät: | , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2023-11-01
|
| Sarja: | Frontiers in Oncology |
| Aiheet: | |
| Linkit: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1110807/full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|